bioAffinity Technologies Management
Management criteria checks 2/4
bioAffinity Technologies' CEO is Maria Zannes, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is $424.17K, comprised of 55.8% salary and 44.2% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth $241.57K. The average tenure of the management team and the board of directors is 1.5 years and 6.6 years respectively.
Key information
Maria Zannes
Chief executive officer
US$424.2k
Total compensation
| CEO salary percentage | 55.8% |
| CEO tenure | 10.9yrs |
| CEO ownership | 1.6% |
| Management average tenure | 1.5yrs |
| Board average tenure | 6.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | -US$9m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$424k | US$237k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$385k | US$253k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$7m |
| Dec 31 2021 | US$264k | US$220k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Dec 31 2020 | US$286k | US$220k | -US$7m |
Compensation vs Market: Maria's total compensation ($USD424.17K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Maria's compensation has increased whilst the company is unprofitable.
CEO
Maria Zannes (68 yo)
10.9yrs
Tenure
US$424,167
Compensation
Ms. Maria Zannes, J.D., serves as the President and Chief Executive Officer of bioAffinity Technologies, Inc. since 2014. Ms. Zannes is the Founder of bioAffinity Technologies, Inc. in 2014. She has been D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman of the Board | 10.8yrs | US$248.75k | 6.89% $ 1.1m | |
| Founder | 10.9yrs | US$424.17k | 1.56% $ 241.6k | |
| CFO & Principal Accounting Officer | less than a year | US$244.58k | 0.73% $ 113.1k | |
| Chief Operating Officer | 7.9yrs | no data | 0.13% $ 20.2k | |
| Chief Science Officer | less than a year | no data | no data | |
| Executive VP | no data | no data | 0.30% $ 45.8k | |
| Director of Communications | 1.8yrs | no data | no data | |
| Vice President of sales | 1.1yrs | no data | no data |
1.5yrs
Average Tenure
68yo
Average Age
Experienced Management: BIAF's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman of the Board | 10.8yrs | US$248.75k | 6.89% $ 1.1m | |
| Founder | 10.8yrs | US$424.17k | 1.56% $ 241.6k | |
| Independent Director | 6.6yrs | US$102.50k | 0.75% $ 116.6k | |
| Independent Director | 2.9yrs | US$105.00k | 0.64% $ 98.4k | |
| Independent Director | 10.8yrs | US$100.00k | 1.05% $ 162.8k | |
| Member of Science & Medical Advisory Board | no data | no data | no data | |
| Member of Science & Medical Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 7.2yrs | US$102.47k | 0.94% $ 145.5k | |
| Member of Science & Medical Advisory Board | no data | no data | no data | |
| Member of Science & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | 2.1yrs | no data | no data | |
| Director | 1.3yrs | US$25.00k | 4.17% $ 645.1k |
6.6yrs
Average Tenure
73yo
Average Age
Experienced Board: BIAF's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:13 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bioAffinity Technologies, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |